Biogen Idec CEO to retire
Cambridge-based biotech Biogen Idec, the maker of the multiple sclerosis drug Tysabri, linkurl:announced;https://investor.biogenidec.com/phoenix.zhtml?c=148682&p=irol-newsArticle&ID=1370474&highlight=] yesterday that its president and CEO, James Mullen, will retire in June. The search is on for a new head. Mullen rose through the ranks at Biogen after coming on as director of facilities and engineering in 1989. He became head of Biogen in 2000, and kept that post when Biogen merged with San Die
Written byAlla Katsnelson
| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
**__Related stories:__***linkurl:MS drug sickens patient...again;https://www.the-scientist.com/blog/display/55285/
[16th December 2008]*linkurl:The urge to merge;https://www.the-scientist.com/blog/display/15748/
[26th September 2005]*linkurl:When bad news strikes;https://www.the-scientist.com/blog/display/14931/
[13th September 2004]
Interested in reading more?
The Scientist ARCHIVES
Become a Member of
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here
Add The Scientist as a preferred Google source to see more of our trusted coverage.
Meet the Author
- This person does not yet have a bio.View Full Profile
